Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 81Colorectal Neoplasms 72Rectal Neoplasms 47Colonic Neoplasms 25Pancreatic Neoplasms 24Neoplasm Metastasis 17Carcinoma, Hepatocellular 17Esophageal Neoplasms 11Cholangiocarcinoma 9Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Biliary Tract Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Gallbladder Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Locally Advanced Rectal Cancer 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Adenocarcinoma 3Solid Tumors 2Solid Tumor 2Ovarian Neoplasms 2Neurotoxicity Syndromes 2Lymphoma 2Lung Neoplasms 2Locally Advanced Colon Cancer 2

Interventions

S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mCRC × Oxaliplatin × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡